Table 2.
Conventional therapeutic options.
| Treatment Approach | Patient Population | Results | Survival | References |
|---|---|---|---|---|
| HMAs | MPN-BP (n = 26); MPN-AP (n = 28) | ORR, 52% with azacitidine | 11 months | [52] |
| MPN-BP (n = 19) | ORR, 47% with azacitidine | 9.9 months | [53] | |
| MPN-BP (n = 21); MPN-AP (n = 13); PMF (n = 11) | ORR in MPN-BP, 29% with decitabine | 6.9 months | [54] | |
| JAK inhibition | R/R AML (n = 38), including MPN-BP (n = 18) | CR/CRi 17% | NR | [55] |
| R/R AML (n = 28), including MPN-BP (n = 7) | ORR, 0% | NR | [56] | |
| JAK inhibition + HMAs | MPN-BP/AP (n = 21) | ORR; 33% | 10.4 months | [57] |
| MPN-BP (n = 10) | ongoing | NR | [58] |
Abbreviations: HMAs, hypomethylating agents; ORR, overall response rate.